Post Date: October 24, 2022
Total Time: 24:40 | File Size: 34 MB
Articles Covered in this Edition
Effects Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. Solomon et al. N Engl J Med 2022;387(12):1089-1098. https://doi.org/10.1056/NEJMoa2206286.
Herpes Zoster Incidence and Burden in Adults With Type 2 Diabetes in the U.S.: A Retrospective Database Analysis. Poirrier et al. Diabetes Care 2022;45(11):2585–2593. https://doi.org/10.2337/dc21-2053.
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Heerspink et al. Lancet Diabetes Endocrinol 2022;10(11):774-785. https://doi.org/10.1016/S2213-8587(22)00243-1.
Productivity Loss and Medical Costs Associated With Type 2 Diabetes Among Employees Aged 18–64 Years With Large Employer-Sponsored Insurance. Park et al. Diabetes Care 2022;45(11):2553–2560. https://doi.org/10.2337/dc22-0445.
Initiation of New Glucose-Lowering Therapies May Act to Reduce Physical Activity Levels: Pooled Analysis From Three Randomized Trials. Yates et al. Diabetes Care 2022;45(11):2749–2752. https://doi.org/10.2337/dc22-0888.
Risk Factors for the Development of Retinopathy in Prediabetes and Type 2 Diabetes: The Diabetes Prevention Program Experience. White et al. Diabetes Care 2022;45(11):2653–2661. https://doi.org/10.2337/dc22-0860.
For more information about each of ADA’s science and medical journals, please visit diabetesjournals.org.